VIDEO: Trial to assess breast cancer treatment in patients with, without brain metastasis
Click Here to Manage Email Alerts
In a video interview, Nancy U. Lin, MD, discussed the DESTINY-Breast12 trial in progress presented at the virtual ESMO Congress.
Lin, associate chief in the Division of Breast Oncology at Susan F. Smith Center for Women's Cancers, director of the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School, said the trial will examine trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) for monotherapy in two cohorts of patients with metastatic HER2-positive breast cancer —those with and those without brain metastases.
“The hope is that this is going to further define the activity of [trastuzumab deruxtecan] in both of these populations when used a bit earlier in the disease setting,” she told Healio.
Collapse
Lin NU, et al. Abstract 335TiP. Presented at: European Society for Medical Oncology Congress (virtual meeting); Sept. 16-21, 2021.
Click Here to Manage Email Alerts